Sonova (OTCMKTS:SONVY) Upgraded at Zacks Research

Zacks Research upgraded shares of Sonova (OTCMKTS:SONVY) from a strong sell rating to a hold rating in a report published on Monday morning,Zacks.com reports.

A number of other research firms have also recently commented on SONVY. Royal Bank Of Canada upgraded Sonova to a “moderate buy” rating in a report on Tuesday, November 18th. BNP Paribas Exane began coverage on shares of Sonova in a research report on Monday, October 20th. They set an “underperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Sonova Price Performance

Shares of SONVY stock opened at $52.14 on Monday. The firm’s fifty day moving average price is $52.94 and its two-hundred day moving average price is $54.46. Sonova has a 1 year low of $47.55 and a 1 year high of $68.76. The company has a current ratio of 1.24, a quick ratio of 0.91 and a debt-to-equity ratio of 0.51.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.